Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS). The ...
Over the past 12 months, MSCI World Net USD has changed by 16.77%. What Is the 52-Week Range for MSCI World Net USD? The MSCI World Net USD stock price has ranged from 10,021.66 to 14,211.46 over the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback